Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

BSX US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Boston Scientific Corp(BSX US)

$44.20-0.932.06%Ext:$44.26+0.060.13%(Pre-Market · 14:25:31 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

BSX US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Boston Scientific Corp(BSX US)

$44.20-0.932.06%Ext:$44.26+0.060.13%(Pre-Market · 14:25:31 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Boston Scientific Corp — Company Profile

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Michael F. Mahoney
Headquarters
Marlborough, MA, US
IPO Date
May 19, 1992
Employees
59,000
Website
www.bostonscientific.com

Key Metrics

Price
$42.60
Market Cap
$63.32B
Revenue (TTM)
$5.20B
Net Income (TTM)
$1.34B
EPS (TTM)
0.90
P/E (TTM)
17.82
P/B (TTM)
2.45
Dividend Yield
0.00%
ROE (TTM)
5.17%
ROA (TTM)
3.01%
Operating Margin
20.60%
Beta
0.20

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Website
www.bostonscientific.com
Location
Marlborough, MA, US
Phone508 683 4000
Employees59,000
CEOMichael F. Mahoney
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMay 19, 1992

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(4.8K)

Expand
  • Form 4Mahoney Michael F6 Nov
  • SC 13G/ARenovoRx, Inc.6 Nov
  • Form 4O'Sullivan Miriam3 Nov
  • 10-QQ3ended 30 Sept 20262 Nov
  • 8-KResults of Operations and Financial Condition28 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers7 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers23 Sep
  • 8-K<ITEMS>1.058 Sep
  • Form 4O'Connor Padraig Andrew3 Sep
  • Form 4Morano Susan E26 Aug
  • 8-KOther Events26 Aug
  • Form 4Woodworth Emily12 Aug
  • Form 4Monson Jonathan11 Aug
  • Form 4Habiger David C7 Aug
  • SC 13G/ABOSTON SCIENTIFIC CORP6 Aug
  • Form 4Habiger David C5 Aug
  • Form 4Mahoney Michael F5 Aug
  • Form 4LUDWIG EDWARD J3 Aug
  • Form 4Fitzgerald Joseph Michael3 Aug
  • 10-QQ2ended 30 Jun 20263 Aug

News

  • Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown12 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX12 Nov
  • AMG National Trust Bank Acquires 34,303 Shares of Boston Scientific Corporation $BSX12 Nov
  • Boston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript11 Nov
  • Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 202711 Nov
  • Insider Buying Signals: 3 Healthcare Stocks to Watch11 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX10 Nov
  • Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy?10 Nov
  • Boston Scientific Corporation $BSX Stock Bought by Ethic Inc.9 Nov
  • BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX5 Nov
  • Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock5 Nov
  • BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak4 Nov
  • Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?3 Nov
  • Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock2 Nov
  • SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints2 Nov
  • Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?30 Oct
  • Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.30 Oct
  • New Strong Sell Stocks for October 30th30 Oct
  • Penumbra, Inc. Reports Third Quarter 2026 Financial Results29 Oct
  • BSX Q3 Earnings Call Flags Growth Challenges Through 202729 Oct

Mentions in Filings

  • … bstantially all of the assets related to our business of developing, commercializing, manufacturing, selling and marketing our cardiac implantable electronic device (“CIED”) products, EluPro™ and CanGaroo®, to <strong>Boston Scientific Corporation</strong> (“BSC”) and Cardiac Pacemakers Inc (“CPI”) for an aggregate purchase price of up to $88.0 million in cash. EluPro was the first antibiotic-eluting biologic matrix envelope for use with CIEDs. This transaction r …
    ELUTIA INC.Boston Scientific Corp·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … g Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by <strong>Boston Scientific Corporation</strong>. Mr. Sherman has served on the board of directors of Aktis Oncology, Inc., a publicly traded life sciences company, since July 2025, and currently serves on the board of directors of a privately held life scien …
    Werewolf Therapeutics, Inc.Boston Scientific Corp·S-4/A - Registration statement (business combination, amendment)·Q4 26·10 Nov
  • … n the Virtue SAB in the Treatment of Coronary In-Stent Restenosis (“ISR”) Trial (the “Virtue Trial”) for our global investigational device exemption (“IDE”) pivotal trial comparing Virtue SAB head-to-head with <strong>Boston Scientific Corporation</strong>’s commercially available AGENT™ paclitaxel-coated balloon. Designed to support regulatory approval of Virtue SAB, the Virtue Trial is expected to enroll 740 patients in the United States with enrollment expecte …
    Orchestra BioMed Holdings, Inc.Boston Scientific Corp·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … tal Line is a privately owned distribution company active in the specialty pharmaceutical and medical device markets and operates in Greece and Cyprus with partnerships with world leaders in medical devices, such as <strong>Boston Scientific</strong>, LeMaitre Vascular, Panther Healthcare and others. **Allen Baharaff, President and Chief Executive Officer of Eocene, commented:** *“CG-100 was developed to address one of the greatest challenges in colorectal surg …
    EoCene Ltd.Boston Scientific Corp·EX-99.1 - 6-K - Current report (foreign private issuer)·Q4 26·10 Nov
  • … ., a company commercializing technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr. Seaberg served at Guidant Corp. (subsequently acquired by <strong>Boston Scientific</strong> Corp.) where he held various executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Manage …
    Anteris Technologies Global Corp.Boston Scientific Corp·ARS - Annual report to security holders·FY25·9 Nov
  • … ., a company commercializing technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr. Seaberg served at Guidant Corp. (subsequently acquired by <strong>Boston Scientific</strong> Corp.) where he held various executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Manage …
    Anteris Technologies Global Corp.Boston Scientific Corp·DEF 14A - Definitive proxy statement·Q4 26·9 Nov

Key Stats

Trading

Px/Chg 1D$42.60 / -1.46%
Prev Close$47.80
% of 52Wk H41.08%
Avg Volume18.05M
Beta0.20
Mkt Cap63.32B
FD Mkt Cap66.86B

Float

Shrs Out/Float1.49B / 1.48B
Short Float0.02%
Days to Cover1.19
Stock Repurchased$0.00

Current Valuation

EV73.06B
EV/EBITDA12.91
EV/Sales3.54
P/B2.45
P/S3.07
FCF Yield0.27%
ROE5.17%
ROA3.01%
Current Ratio1.90

Estimates

P/E17.82
Est P/E0.00
Est EPS0.79
Est PEG0.00

Valuation

Metric5Yr AvgMay '23Apr '24Apr '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings88.49107.9865.5581.65139.6847.60
Price / Sales10.445.947.339.0417.6512.23
Price / Book Value4.594.295.426.953.852.46
Price / Free Cash Flow133.0682.4761.3257.2392.11372.15
ENTERPRISE VALUE METRICS
Enterprise Value107,334.083,727.0113,302.1162,339.2103,918.373,383.5
Enterprise Value / Sales11.606.607.969.6919.6614.10
Enterprise Value / EBITDA45.8130.5532.8141.2278.6745.78
Enterprise Value / EBIT66.1052.1750.2060.82108.7058.61

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue14%11,888.012,682.014,240.016,747.020,074.0
Gross Income16.7%7,461.07,714.08,831.010,267.013,853.0
EBITDA19.3%2,518.02,741.03,453.03,938.05,102.0
EBIT27.2%1,425.01,605.02,257.02,669.03,734.0
Net Income29.1%1,040.0698.01,593.01,854.02,886.0
EPS (Diluted)29.6%0.690.451.071.251.94
BALANCE SHEET
Cash & ST Inv1.5%1,925.0928.0865.0414.02,045.0
Total Assets7.9%32,230.032,470.035,136.039,395.043,673.0
Total Liabilities5.3%15,607.014,896.015,606.017,392.019,201.0
Total Shareholder Equity9.9%16,623.017,574.019,282.021,770.024,233.0
CASH FLOW
Net Operating Cash Flow24.8%1,871.01,526.02,503.03,435.04,534.0
Cap Ex12.1%-554.0-612.0-800.0-790.0-876.0
Free Cash Flow29.1%1,316.0914.01,703.02,645.03,658.0

Enterprise Value Bridge

Millions USD12 Nov '26
Price (As of 12 Nov '26)44.23
Basic Shares1,486.36
Market Cap65,736.8
Diluted Shares1,452.00
Fully Diluted Shares Outstanding1,452.00
Fully Diluted Market Cap64,217.2
+Consolidated Debt11,953.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-609.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest243.0
+Pension Liabilities—
Enterprise Value77,323.8

Segment data

Revenue

by Products and services

  • Cardiovascular66%
  • Medsurg34%

Revenue

by Geography

  • United States64%
  • Non-us36%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US

Boston Scientific Corp — Company Profile

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UN
CEO
Michael F. Mahoney
Headquarters
Marlborough, MA, US
IPO Date
May 19, 1992
Employees
59,000
Website
www.bostonscientific.com

Key Metrics

Price
$42.60
Market Cap
$63.32B
Revenue (TTM)
$5.20B
Net Income (TTM)
$1.34B
EPS (TTM)
0.90
P/E (TTM)
17.82
P/B (TTM)
2.45
Dividend Yield
0.00%
ROE (TTM)
5.17%
ROA (TTM)
3.01%
Operating Margin
20.60%
Beta
0.20

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Website
www.bostonscientific.com
Location
Marlborough, MA, US
Phone508 683 4000
Employees59,000
CEOMichael F. Mahoney
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateMay 19, 1992

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(4.8K)

Expand
  • Form 4Mahoney Michael F6 Nov
  • SC 13G/ARenovoRx, Inc.6 Nov
  • Form 4O'Sullivan Miriam3 Nov
  • 10-QQ3ended 30 Sept 20262 Nov
  • 8-KResults of Operations and Financial Condition28 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers7 Oct
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers23 Sep
  • 8-K<ITEMS>1.058 Sep
  • Form 4O'Connor Padraig Andrew3 Sep
  • Form 4Morano Susan E26 Aug
  • 8-KOther Events26 Aug
  • Form 4Woodworth Emily12 Aug
  • Form 4Monson Jonathan11 Aug
  • Form 4Habiger David C7 Aug
  • SC 13G/ABOSTON SCIENTIFIC CORP6 Aug
  • Form 4Habiger David C5 Aug
  • Form 4Mahoney Michael F5 Aug
  • Form 4LUDWIG EDWARD J3 Aug
  • Form 4Fitzgerald Joseph Michael3 Aug
  • 10-QQ2ended 30 Jun 20263 Aug

News

  • Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown12 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX12 Nov
  • AMG National Trust Bank Acquires 34,303 Shares of Boston Scientific Corporation $BSX12 Nov
  • Boston Scientific Corporation (BSX) Presents at Stifel 2026 Healthcare Conference 2026 Transcript11 Nov
  • Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 202711 Nov
  • Insider Buying Signals: 3 Healthcare Stocks to Watch11 Nov
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX10 Nov
  • Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy?10 Nov
  • Boston Scientific Corporation $BSX Stock Bought by Ethic Inc.9 Nov
  • BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX5 Nov
  • Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock5 Nov
  • BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak4 Nov
  • Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?3 Nov
  • Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock2 Nov
  • SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints2 Nov
  • Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?30 Oct
  • Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.30 Oct
  • New Strong Sell Stocks for October 30th30 Oct
  • Penumbra, Inc. Reports Third Quarter 2026 Financial Results29 Oct
  • BSX Q3 Earnings Call Flags Growth Challenges Through 202729 Oct

Mentions in Filings

  • … bstantially all of the assets related to our business of developing, commercializing, manufacturing, selling and marketing our cardiac implantable electronic device (“CIED”) products, EluPro™ and CanGaroo®, to <strong>Boston Scientific Corporation</strong> (“BSC”) and Cardiac Pacemakers Inc (“CPI”) for an aggregate purchase price of up to $88.0 million in cash. EluPro was the first antibiotic-eluting biologic matrix envelope for use with CIEDs. This transaction r …
    ELUTIA INC.Boston Scientific Corp·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … g Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by <strong>Boston Scientific Corporation</strong>. Mr. Sherman has served on the board of directors of Aktis Oncology, Inc., a publicly traded life sciences company, since July 2025, and currently serves on the board of directors of a privately held life scien …
    Werewolf Therapeutics, Inc.Boston Scientific Corp·S-4/A - Registration statement (business combination, amendment)·Q4 26·10 Nov
  • … n the Virtue SAB in the Treatment of Coronary In-Stent Restenosis (“ISR”) Trial (the “Virtue Trial”) for our global investigational device exemption (“IDE”) pivotal trial comparing Virtue SAB head-to-head with <strong>Boston Scientific Corporation</strong>’s commercially available AGENT™ paclitaxel-coated balloon. Designed to support regulatory approval of Virtue SAB, the Virtue Trial is expected to enroll 740 patients in the United States with enrollment expecte …
    Orchestra BioMed Holdings, Inc.Boston Scientific Corp·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … tal Line is a privately owned distribution company active in the specialty pharmaceutical and medical device markets and operates in Greece and Cyprus with partnerships with world leaders in medical devices, such as <strong>Boston Scientific</strong>, LeMaitre Vascular, Panther Healthcare and others. **Allen Baharaff, President and Chief Executive Officer of Eocene, commented:** *“CG-100 was developed to address one of the greatest challenges in colorectal surg …
    EoCene Ltd.Boston Scientific Corp·EX-99.1 - 6-K - Current report (foreign private issuer)·Q4 26·10 Nov
  • … ., a company commercializing technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr. Seaberg served at Guidant Corp. (subsequently acquired by <strong>Boston Scientific</strong> Corp.) where he held various executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Manage …
    Anteris Technologies Global Corp.Boston Scientific Corp·ARS - Annual report to security holders·FY25·9 Nov
  • … ., a company commercializing technology developed at the Mayo Clinic for repair of the mitral valve via minimally invasive techniques. From 1996 to 2006, Mr. Seaberg served at Guidant Corp. (subsequently acquired by <strong>Boston Scientific</strong> Corp.) where he held various executive level positions, including Director of Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery and Vice President of Sales for Cardiac Rhythm Manage …
    Anteris Technologies Global Corp.Boston Scientific Corp·DEF 14A - Definitive proxy statement·Q4 26·9 Nov

Key Stats

Trading

Px/Chg 1D$42.60 / -1.46%
Prev Close$47.80
% of 52Wk H41.08%
Avg Volume18.05M
Beta0.20
Mkt Cap63.32B
FD Mkt Cap66.86B

Float

Shrs Out/Float1.49B / 1.48B
Short Float0.02%
Days to Cover1.19
Stock Repurchased$0.00

Current Valuation

EV73.06B
EV/EBITDA12.91
EV/Sales3.54
P/B2.45
P/S3.07
FCF Yield0.27%
ROE5.17%
ROA3.01%
Current Ratio1.90

Estimates

P/E17.82
Est P/E0.00
Est EPS0.79
Est PEG0.00

Valuation

Metric5Yr AvgMay '23Apr '24Apr '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings88.49107.9865.5581.65139.6847.60
Price / Sales10.445.947.339.0417.6512.23
Price / Book Value4.594.295.426.953.852.46
Price / Free Cash Flow133.0682.4761.3257.2392.11372.15
ENTERPRISE VALUE METRICS
Enterprise Value107,334.083,727.0113,302.1162,339.2103,918.373,383.5
Enterprise Value / Sales11.606.607.969.6919.6614.10
Enterprise Value / EBITDA45.8130.5532.8141.2278.6745.78
Enterprise Value / EBIT66.1052.1750.2060.82108.7058.61

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue14%11,888.012,682.014,240.016,747.020,074.0
Gross Income16.7%7,461.07,714.08,831.010,267.013,853.0
EBITDA19.3%2,518.02,741.03,453.03,938.05,102.0
EBIT27.2%1,425.01,605.02,257.02,669.03,734.0
Net Income29.1%1,040.0698.01,593.01,854.02,886.0
EPS (Diluted)29.6%0.690.451.071.251.94
BALANCE SHEET
Cash & ST Inv1.5%1,925.0928.0865.0414.02,045.0
Total Assets7.9%32,230.032,470.035,136.039,395.043,673.0
Total Liabilities5.3%15,607.014,896.015,606.017,392.019,201.0
Total Shareholder Equity9.9%16,623.017,574.019,282.021,770.024,233.0
CASH FLOW
Net Operating Cash Flow24.8%1,871.01,526.02,503.03,435.04,534.0
Cap Ex12.1%-554.0-612.0-800.0-790.0-876.0
Free Cash Flow29.1%1,316.0914.01,703.02,645.03,658.0

Enterprise Value Bridge

Millions USD12 Nov '26
Price (As of 12 Nov '26)44.23
Basic Shares1,486.36
Market Cap65,736.8
Diluted Shares1,452.00
Fully Diluted Shares Outstanding1,452.00
Fully Diluted Market Cap64,217.2
+Consolidated Debt11,953.0
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-609.0
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest243.0
+Pension Liabilities—
Enterprise Value77,323.8

Segment data

Revenue

by Products and services

  • Cardiovascular66%
  • Medsurg34%

Revenue

by Geography

  • United States64%
  • Non-us36%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

L3harris Technologies, Inc. /DE/

LHX US